Coronavirus Notebook: Bivalent Spikevax OKd For Filing In Australia, Pfizer & Moderna Under Growing Pressure To Share mRNA Knowhow
Executive Summary
The World Health Organization and UNICEF say that disruptions caused by COVID-19 and actions taken to tackle the pandemic have left many children without protection against measles and other diseases. Austria’s Apeiron has given an update on the development of its candidate therapeutic, APN01.
You may also be interested in...
Coronavirus Notebook: 35 Generic Firms To Produce Pfizer’s Paxlovid, AZ’s Evusheld Gains UK & Australian Approval
Finland’s Rokote expects to begin clinical trials with its intranasal vaccine after the summer, while Australia’s ENA Respiratory has dosed the first patients in a Phase IIa study of its antiviral nasal spray.
New Zealand Hikes Fees To Reflect Changes In Drug Applications
Following a consultation last year, Medsafe has set new fee levels that take account of both cost-recovery principles and a 4.2% increase in the consumer price index.
Bavarian Nordic To Supply Vaccine As Monkeypox Appears In UK & Portugal
The monkeypox cases reported this month are evidence of chains of transmission of the virus, according to the European Centre for Disease Prevention and Control, which says that vaccination of high-risk close contacts should be considered after a benefit-risk assessment.